Table 1

Clinical characteristics in 667 participants with type 1 diabetes with or without a cardiovascular event stratified by the occurrence of a CVE during a median of 5.1 years of follow-up

Without a CVEWith a CVEP
Number of participants57394
Female (%)47340.033
Age (years)54 ± 1361 ± 9<0.001
Diabetes duration (years)31 ± 1641 ± 13<0.001
eGFR (mL/min/1.73 m2)84 ± 2567 ± 26<0.001
UAER (mg/24 h)14.5 (7.6–52.5)47.9 (20.0–218.8)<0.001
HbA1c (mmol/mol)64 ± 1368 ± 120.005
HbA1c (%)8 ± 1.211 ± 1.10.005
HDL cholesterol (mmol/L)1.7 ± 0.51.6 ± 0.60.08
LDL cholesterol (mmol/L)2.4 ± 0.72.6 ± 0.90.07
BMI (kg/m2)25.4 ± 6.025.7 ± 4.10.65
Treatment with
 Antihypertensive drugs (%)6799<0.001
 Diuretics (%)4679<0.001
 RAAS blockers (%)6393<0.001
 Antiplatelet agent* (%)4881<0.001
 Statins (%)5781<0.001
 Smokers (%)20220.68
Systolic blood pressure (mmHg)131 ± 17137 ± 190.001
Diastolic blood pressure (mmHg)74 ± 973 ± 100.007
Plasma uric acid (mmol/L)0.29 (0.23–0.35)0.37 (0.29–0.47)<0.001
  • Data represent percentage (%), mean ± SD, or median (IQR). P values represent differences between participants with or without a CVE. CVE, cardiovascular event.

  • *Antiplatelets are acetylcalic acid and clopidogrel.